Skip to main content
Premium Trial:

Request an Annual Quote

Centogene, Evotec Forge Drug-Discovery Alliance

NEW YORK (GenomeWeb) — German multiomics tools firm Centogene announced today that it has partnered with Evotec to discover and develop drugs for certain rare genetic diseases.

Under the terms of the strategic alliance, the companies will combine Evotec's induced pluripotent stem cell-based drug screening platform with Centogene's patient access and biomarker expertise to develop a high-throughput platform for evaluating novel small molecule treatments for rare hereditary metabolic diseases.

Additional terms were not disclosed.

"The identification and development of innovative small molecules to treat rare hereditary conditions is particularly challenging because of the absence of adequate cellular models and the general lack of specific biomarkers to monitor the different diseases," Centogene CEO Arndt Rolfs said in a statement. "With this innovative collaboration between Evotec and Centogene, we can accelerate the development of new drugs."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.